648.73
2.20 (0.34%)
| Previous Close | 646.53 |
| Open | 641.09 |
| Volume | 400,090 |
| Avg. Volume (3M) | 548,995 |
| Market Cap | 51,901,444,096 |
| Price / Earnings (TTM) | 49.52 |
| Price / Earnings (Forward) | 45.25 |
| Price / Sales | 12.14 |
| Price / Book | 32.06 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2026 |
| Profit Margin | 22.76% |
| Operating Margin (TTM) | 31.70% |
| Diluted EPS (TTM) | 10.82 |
| Quarterly Revenue Growth (YOY) | 3.60% |
| Quarterly Earnings Growth (YOY) | 3.00% |
| Total Debt/Equity (MRQ) | 73.16% |
| Current Ratio (MRQ) | 1.16 |
| Operating Cash Flow (TTM) | 968.38 M |
| Levered Free Cash Flow (TTM) | 761.15 M |
| Return on Assets (TTM) | 22.98% |
| Return on Equity (TTM) | 59.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | IDEXX Laboratories, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | 3.0 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.90 |
|
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.67% |
| % Held by Institutions | 97.51% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Elyxium Wealth, Llc | 31 Dec 2025 | 5,419,507 |
| Fundsmith Llp | 30 Sep 2025 | 2,610,457 |
| Polen Capital Management Llc | 30 Sep 2025 | 1,127,147 |
| Blair William & Co/Il | 30 Sep 2025 | 1,031,786 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 800.00 (Barclays, 23.32%) | Buy |
| 800.00 (BTIG, 23.32%) | Buy | |
| Median | 775.00 (19.46%) | |
| Low | 730.00 (UBS, 12.53%) | Hold |
| Average | 770.00 (18.69%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 637.13 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 09 Feb 2026 | 750.00 (15.61%) | Hold | 639.79 |
| Barclays | 05 Feb 2026 | 800.00 (23.32%) | Buy | 643.59 |
| 09 Dec 2025 | 850.00 (31.03%) | Buy | 699.06 | |
| BTIG | 03 Feb 2026 | 800.00 (23.32%) | Buy | 632.56 |
| UBS | 03 Feb 2026 | 730.00 (12.53%) | Hold | 632.56 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Feb 2026 | Announcement | IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results |
| 15 Jan 2026 | Announcement | Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus |
| 15 Jan 2026 | Announcement | IDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs |
| 13 Jan 2026 | Announcement | IDEXX Announces CEO Succession |
| 09 Jan 2026 | Announcement | IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |